We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

CLSN
Celsion Corp.
NasdaqCM
People also watch : CYCC IMUC CPRX THLD ONTY
1.28 0.00 (0.00%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close 1.28
Open 1.30
Bid 1.27 x 700
Ask 1.29 x 9400
52wk Range 1.04 - 2.55
Day's Range 1.26 - 1.30
Volume 41,085
Avg Vol (3m) 68,330
As of 4:00 PM EDT. Market closed.
  • Capital Cube 7 days ago

    ETF’s with exposure to Celsion Corp. : July 20, 2016

    Click here to see latest analysis*Disclaimer : This is as of previous day’s closeETF’s with exposure to Celsion Corp.Here are 5 ETF’s with the largest exposure to CLSN-US. Comparing the performance and risk of Celsion Corp. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns […] (Read more...) The post ETF’s with exposure to Celsion Corp. : July 20, 2016 appeared first on CapitalCube.

  • 24/7 Wall St. 10 days ago

    4 Speculative Biotech and Biohealth Analysts Calls for Huge Upside

    Investors in the biotech and biohealth space generally are taking on much more risk than in the likes of most Dow and S&P 500 stocks. That means they will demand more potential upside for that risk.

  • Celsion Corp. :CLSN-US: Earnings Analysis: Q1, 2016 By the Numbers : June 7, 2016
    Capital Cube 2 months ago

    Celsion Corp. :CLSN-US: Earnings Analysis: Q1, 2016 By the Numbers : June 7, 2016

    Click here to see latest analysisCelsion Corp. reports financial results for the quarter ended March 31, 2016.We analyze the earnings along side the following peers of Celsion Corp. – Threshold Pharmaceuticals, Inc., ArQule, Inc., Cerulean Pharma, Inc., Endocyte, Inc., Spectrum Pharmaceuticals, Inc., ZIOPHARM Oncology, Inc., ImmunoGen, Inc., Exelixis, Inc. and Keryx Biopharmaceuticals, Inc. (THLD-US, ARQL-US, […] (Read more...) The post Celsion Corp. :CLSN-US: Earnings Analysis: Q1, 2016 By the Numbers : June 7, 2016 appeared first on CapitalCube.

  • Zacks 3 months ago

    Should You Buy Celsion (CLSN) Ahead of Earnings?

    Celsion (CLSN) looks poised to beat analyst estimates this earnings season, with a favourable Zacks Rank and an ESP in positive territory.

  • Celsion Corp. :CLSN-US: Earnings Analysis: Q4, 2015 By the Numbers
    Capital Cube 4 months ago

    Celsion Corp. :CLSN-US: Earnings Analysis: Q4, 2015 By the Numbers

    Click here to see latest analysisCelsion Corp. reports financial results for the quarter ended December 31, 2015.HighlightsSummary numbers: Revenues of USD 0.13 million, Net Earnings of USD -5.51 million.Change in operating cash flow of 40.10% compared to same period last year is about the same as change in earnings, likely no significant movement in accruals […] (Read more...) The post Celsion Corp. :CLSN-US: Earnings Analysis: Q4, 2015 By the Numbers appeared first on CapitalCube.

  • Thomson Reuters StreetEvents 4 months ago

    Edited Transcript of CLSN earnings conference call or presentation 30-Mar-16 3:00pm GMT

    Q4 2015 Celsion Corp Earnings Call

  • Zacks 5 months ago

    Celsion (CLSN) Provides Pipeline Update, GEN-1 in Focus

    Celsion Corp. (CLSN) provided an update on its GEN-1 immunotherapy pipeline.

  • Zacks 8 months ago

    New Strong Buy Stocks for December 9th

    Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday

  • Zacks 8 months ago

    New Strong Buy Stocks for November 24th

    Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday